Research programme: antibacterials - Durata

Drug Profile

Research programme: antibacterials - Durata

Alternative Names: 7-Methyl lincosamides - Durata; Lincosamides - Durata; Peptide deformylase inhibitors - Durata; PF-03438011; PF-03438012; VIC 105403; VIC 105404; VIC 105555; VIC 200603; VIC 5555; VIC 603; VRC-3950

Latest Information Update: 30 Dec 2014

Price : $50

At a glance

  • Originator Vicuron Pharmaceuticals
  • Class Azetidines; Ketolides; Macrocyclic compounds; Sulfonamides
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections
  • Discontinued Mycoses

Most Recent Events

  • 06 Oct 2014 Durata Therapeutics enters into a definitive merger agreement with Actavis
  • 27 Jan 2006 Data presented at the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC-2005) have been added to the pharmacokinetics and Bacterial infections antimicrobial activity ,,," />) and pharmacodynamics sections
  • 11 Sep 2005 Vicuron Pharmaceuticals has been acquired and merged into Pfizer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top